EOM 1352: Fri 7 June 2024, 11:36
Media Pack
News

Current Edition

Volume 18, Issue 1
Discovery Park: Wed 13 November 2024, 10:35
ramusmedical
Regional News

Novo Nordisk, trying to switch patients to Rybelsus, launches new TV ad

Down with Rybelsus! No, this isn’t a line from "1984," but rather the new message from Novo Nordisk for its first Rybelsus ad of 2022. One of the biggest issues f...
4 April 2022 Regional News diabetes | FDA
Continue Reading →
Regional News

Zealand becomes a lesson in the rigors of commercialization as a slow launch triggers 90% staff cut, CEO exit

It wasn’t supposed to be this way. Zealand Pharma should be in the honeymoon glow of its first drug launch with a drug approved less than a year ago. Instead, it's lo...
4 April 2022 Regional News diabetes | FDA
Continue Reading →
Regional News

FDA chides Eli Lilly for second misleading ad in 2 months, this time for diabetes blockbuster Trulicity

After neatly wrapping up concerns over a series of Emgality ads last month, Eli Lilly is back in hot water with the FDA's Office of Prescription Drug Promotion. The ...
26 January 2022 Regional News diabetes | drugmaker
Continue Reading →
Regional News

Lawmakers blast pharma for ‘outrageous’ prices and ‘anticompetitive conduct’ in culmination of 3-year probe

For years, drugmakers have targeted "weaknesses" in the U.S. healthcare system to reap dividends on older meds, The House Oversight Committee said Friday. The "outra...
13 December 2021 Regional News diabetes | drug costs
Continue Reading →
Regional News

Viatris launched two versions of its interchangeable insulin biosimilar. Why?

It's official: Biocon and Viatris have launched their historic interchangeable insulin biosimilar, Semglee. The drug, which references Sanofi's blockbuster diabetes m...
17 November 2021 Regional News Biocon | biosimilar
Continue Reading →
Europe

Altasciences Participates in Clinical Trial for Type 1 Diabetes Mellitus

Altasciences is pleased to have partnered with Xeris Pharmaceuticals, a specialty pharmaceutical company leveraging its novel formulation technology platforms to deve...
18 July 2018 Europe Altasciences | clinical
Continue Reading →
Asia Pacific

Janssen to begin phase 2 clinical trials of Hanmi Pharma’s diabetes drug

US pharmaceutical company Janssen will start carrying out phase 2 clinical trials in the US to evaluate the efficacy and safety of a diabetes drug candidate originall...
4 April 2018 Asia Pacific | Europe clinical | diabetes
Continue Reading →
news

Sanofi’s Toujeo® met main objective in head-to-head study versus insulin degludec

Sanofi's Toujeo® met the primary study objective in the first large head-to-head clinical trial1, called BRIGHT study, comparing Toujeo with insulin degludec. Sanofi ...
6 December 2017 news BRIGHT study | clinical trial
Continue Reading →
news

Xultophy® reported a better option than basal-bolus insulin therapy to manage type 2 diabetes by participants in the DUAL VII clinical trial

Once-daily Xultophy® (insulin degludec/liraglutide) was a better option to manage diabetes compared to multiple daily injections of insulin (basal-bolus regimen). Thi...
5 December 2017 news clinical trial | diabetes
Continue Reading →
news

Imcyse continues patient enrolment in its Phase 1b trial in type 1 diabetes

Imcyse, a biotechnology company developing active specific therapies for the treatment of severe chronic diseases, today announces that it began recruiting patients i...
15 November 2017 news clinical | diabetes
Continue Reading →
Catalyst: 12th January 2026
Quotient

jcs-white.png

Journal for Clinical Studies

Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.

Facebook Linkedin
Journal For Clinical Studies © 2026, All Rights Reserved – Powered by Teksyte